Full Press Release Details
FOR IMMEDIATE RELEASE: November 5, 2021
CONTACT: mindmed@150bond.com
MindMed Appoints Dr. Maria Oquendo
to its Scientific Advisory Board
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO:
MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the
appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board.
Dr. Oquendo is Ruth Meltzer Professor and Chairman
of Psychiatry at University of Pennsylvania and Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania. A summa cum laude
graduate of Tufts University, she attended Vagelos College of Physicians and Surgeons at Columbia University. She completed residency
at the Payne Whitney Clinic of New York Hospital Cornell. She is a member of the National Academy of Medicine, one of the highest honors
Dr. Oquendo has used Positron Emission Tomography
and Magnetic Resonance Imaging to map brain abnormalities related to mood disorders and suicidal behavior. She has over 450 peer-reviewed
publications and an h-factor of 78, with over 18,000 citations.
Dr. Oquendo is Past President of the American
Psychiatric Association (APA), the International Academy of Suicide Research, and the American College of Neuropsychopharmacology (ACNP).
She is Vice President of the Board of the American Foundation for Suicide Prevention, Vice President of the College of International Neuropsychopharmacology,
and has served on the National Institute of Mental Health's Advisory Council.
Dr. Oquendo is a member of Tufts University's
Board of Trustees and serves on its Executive Committee. A recipient of multiple awards in the US, Europe and South America, most recently,
she was honored with the Alexandra Symonds Award (APA 2017), the APA's Research Award (2018), the Dolores Shockley Award (ACNP 2018)
and the Alexander Glassman Award (Columbia University 2021).
MindMed CEO Robert Barrow said, "We are
thrilled to welcome Dr. Oquendo to our Scientific Advisory Board. Our goal is to revolutionize mental health and addiction care and we
want to make effective treatments accessible to broad and diverse patient populations from across the globe. Dr. Oquendo's extensive
experience in psychiatry and pharmacology, including her work with high risk patients, will be invaluable in progressing all of our research
and development efforts."
Dr. Oquendo added, "In view of the pharmacologic
actions that compounds like LSD and psilocybin share with putative anti-suicidal drugs, this exciting avenue of investigation may lead
to discoveries of new approaches to this life-threatening behavior."
MindMed's Scientific Advisory Board is composed
of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development. The Scientific Advisory Board leverages
decades of deep knowledge in biotech and psychiatry to guide MindMed's development programs. Members represent institutions such
as Stanford University, University of Pennsylvania, University of Rochester, Boston University, and Massachusetts General Hospital.
MindMed is a clinical-stage psychedelic medicine
biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental
illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience
to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol
MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Forward-Looking Statements
Certain statements in this news release related
to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective
in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future
events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words
such as "will", "may", "should", "could", "intend", "estimate",
"plan", "anticipate", "expect", "believe", "potential" or "continue",
or the negative thereof or similar variations. Although the Company believes that the expectations reflected in such forward-looking information
are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown
or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are
numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of
future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated
with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development;
clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors
discussed or referred to herein and the risks described under the headings "Risk Factors" in the Company's filings with
the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile
on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks
or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future
events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks,
uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management
on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not
intend and does not assume any obligation to update this forward-looking information.
Media Contact: mindmed@150bond.com